Fidelity Investments
EWTX icon

Fidelity Investments’s Edgewise Therapeutics EWTX Stock Holding History

Fidelity Investments’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223M Buy
5,489,135
+4,472,083
+440% +$154M 0.01% 884
2026
Q1 		$32M Buy
1,017,052
+324,097
+47% +$9.35M ﹤0.01% 1597
2025
Q4 		$17.2M Buy
692,955
+439,630
+174% +$8.82M ﹤0.01% 1832
2025
Q3 		$4.11M Sell
253,325
-217,392
-46% -$3.08M ﹤0.01% 2304
2025
Q2 		$6.17M Buy
470,717
+284,694
+153% +$4.11M ﹤0.01% 2089
2025
Q1 		$4.09M Sell
186,023
-62,013
-25% -$1.63M ﹤0.01% 2211
2024
Q4 		$6.62M Sell
248,036
-405,172
-62% -$12.9M ﹤0.01% 2064
2024
Q3 		$17.4M Sell
653,208
-4,127,355
-86% -$82.1M ﹤0.01% 1757
2024
Q2 		$86.1M Sell
4,780,563
-1,585,161
-25% -$27.6M 0.01% 1104
2024
Q1 		$116M Sell
6,365,724
-126,789
-2% -$2.02M 0.01% 995
2023
Q4 		$71M Buy
6,492,513
+89,666
+1% +$630K 0.01% 1152
2023
Q3 		$36.7M Sell
6,402,847
-954,642
-13% -$6.49M ﹤0.01% 1360
2023
Q2 		$57M Sell
7,357,489
-583,053
-7% -$4.92M ﹤0.01% 1230
2023
Q1 		$53M Sell
7,940,542
-648,687
-8% -$6.01M ﹤0.01% 1242
2022
Q4 		$76.8M Buy
8,589,229
+612,416
+8% +$5.74M 0.01% 1070
2022
Q3 		$78.5M Buy
7,976,813
+5,161,529
+183% +$52.2M 0.01% 1050
2022
Q2 		$22.4M Buy
2,815,284
+293,834
+12% +$2.22M ﹤0.01% 1606
2022
Q1 		$24.5M Buy
2,521,450
+21,351
+0.9% +$275K ﹤0.01% 1703
2021
Q4 		$38.2M Sell
2,500,099
-654,573
-21% -$11.8M ﹤0.01% 1535
2021
Q3 		$52.4M Buy
3,154,672
+739,454
+31% +$13.4M ﹤0.01% 1388
2021
Q2 		$51.5M Buy
2,415,218
+884,800
+58% +$24.2M ﹤0.01% 1411
2021
Q1 		$49.7M Buy
+1,530,418
New +$49.6M ﹤0.01% 1402

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments's EWTX Position: Q2 2026 in Review

Fidelity Investments increased its Edgewise Therapeutics (EWTX) stake by 440% in Q2 2026, buying an estimated $154M and bringing the position to 5,489,135 shares worth $223M. The position accounts for 0.01% of the portfolio, ranked #884.

Fidelity Investments first reported a position in EWTX in Q1 2021 and has held it in 22 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Fidelity Investments held 5,489,135 shares of Edgewise Therapeutics worth $223M as of Q2 2026.
  • Fidelity Investments bought 4,472,083 Edgewise Therapeutics shares in Q2 2026, an estimated $154M.
  • Edgewise Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #884 holding.
  • Fidelity Investments first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.